|
|||||
|
|
| 创新医药项目核心价值评估策略 | |
| 引用本文： | 吴宏忠, 任春妍. 创新医药项目核心价值评估策略[J]. 药学进展, 2018, 42(2): 141-147. |
| 作者姓名： | 吴宏忠 任春妍 |
| 作者单位： | 1.华海投资管理有限公司，上海 201203;2.西奈山医学院，纽约 10029 |
| 摘 要： | 创新性医药项目核心价值评估是医药行业产品立项、产品引进、投资并购的核心工作。从未满足临床需求、市场容量、竞争格局、临床成功率、数据、知识产权、研发团队的推进能力等多层面分析创新性医药研发项目核心价值，可以判断该项目的未来商业化前景、创新水平和质量、未来成功实现的可能性，从而降低新药研发的系统性风险。总结和介绍了创新医药项目核心价值评估的策略。 |
| 关 键 词： | 创新药 核心价值 评估 投资决策 系统风险 |
The order of entry effect in prescription (Rx) and over-the-counter (OTC) pharmaceutical drugs |
|
| WU Hongzhong, REN Chunyan. Strategies of Core Value Assessment for Innovative Pharmaceutical Projects[J]. Progress in Pharmaceutical Sciences, 2018, 42(2): 141-147. | |
| Authors: | WU Hongzhong REN Chunyan |
| Affiliation: | 1.Huahai Investment Management Co., Ltd., Shanghai 201203, China;2.Mount Sinai School of Medicine, New York 10029, USA |
| Abstract: | The core value assessment for innovative pharmaceutical projects is the core work of product initiation, product licensing, investment, mergers and acquisitions in pharmaceutical industry. Multi-level analysis of core values of innovative medical projects from the aspects of unmet clinical needs, market capacity, competitive landscape, clinical success rate, data, intellectual property, and the implementation capacity of R & D team can help to evaluate the commercial prospects, innovation quality and the likelihood of future success of these projects, reducing the systematic risk in new drug R & D. The strategies of core value assessment for innovative pharmaceutical projects have been introduced in this paper. |
| Keywords: | innovative drugs core value assessment investment decision systematic risk |
| 点击此处可从《药学进展》浏览原始摘要信息 | |
| 点击此处可从《药学进展》下载全文 | |